Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of PF-03446962 Plus Best Supportive Care Versus Best Supportive Care in Advanced Hepatocellular Carcinoma
KCT0001033Phase 2Not yet recruiting
- Sponsor
- Pfizer
- Start
- Sep 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of ascrinvacumab in hepatocellular carcinoma (HCC), sponsored by Pfizer. Planned start Sep 2014; status: not yet recruiting.
02
Drugs
ascrinvacumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on KCT0001033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001033.